Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
linear decrease » linear increase (Expand Search)
-
2661
-
2662
-
2663
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2664
-
2665
-
2666
-
2667
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2668
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2669
-
2670
-
2671
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2672
-
2673
-
2674
-
2675
-
2676
-
2677
-
2678
-
2679
Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.
Published 2025Subjects: -
2680